Company intelligence / Profile preview

NETRIS Pharma

Lyon, Auvergne-Rhône-Alpes, Francenetrispharma.com ↗

Ownership: Private
Employees: ~16
Development stage: Phase 1

Overview

NETRIS Pharma’s lead asset NP137, a first-in-class humanized monoclonal antibody targeting netrin‑1, has demonstrated an excellent safety profile and promising anti-tumoral activity across several solid tumor indications. As of April 2025, positive interim Phase II results were announced for NP137 in combination with anti-PD(L)1 therapy. The company also received FDA Orphan Drug Designation for pancreatic cancer treatment with NP137.

Therapeutic areas: Women's HealthOncology
Modalities: Monoclonal antibodies (mAbs)Humanized monoclonal antibody (IgG1)
Industry: Biotech

Drug pipeline

4 assets

np137

3 more assets in the full pipeline.

Request access →

Partnerships

MSD (Merck & Co.)ORANOCentre Léon Bérard

Beyond the preview

Go deeper on NETRIS Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NETRIS Pharma.

Explore the full profile